Company: LGNZZ
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000886163-25-000051
Chunk: 6

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-08
Form: 10-Q
Item: Item 1
Chunk 6
---
$(23,168)$34,110 

See accompanying notes to unaudited condensed consolidated financial statements.

6

LIGAND PHARMACEUTICALS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY 

(Unaudited)

(in thousands)

Common StockAdditional paid in capitalAccumulated other comprehensive income (loss)Retained earningsTotal stockholders' equitySharesAmountBalance at December 31, 202419,106 $20 $337,377 $(5,942)$498,984 $830,439 Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes170 — (4,669)— — (4,669)Share-based compensation— — 7,836 — — 7,836 Unrealized loss on available-for-sale securities, net of tax— — — (22)— (22)Foreign currency translation adjustment, net of tax— — — 4,401 — 4,401 Net loss— — — — (42,451)(42,451)Balance at March 31, 202519,276 20 340,544 (1,563)456,533 795,534 Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes135 — 8,094 — — 8,094 Share-based compensation— — 9,997 — — 9,997 Unrealized loss on available-for-sale securities, net of tax— — — (49)— (49)Foreign currency translation adjustment, net of tax— — — 10,106 — 10,106 Net income— — — — 4,847 4,847 Balance at June 30, 202519,411 $20 $358,635 $8,494 $461,380 $828,529 

Common StockAdditional paid in capitalAccumulated other comprehensive lossRetained earnings Total stockholders' equitySharesAmountBalance at December 31, 202317,556 $18 $198,696 $(817)$503,016 $700,913 Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes368 —